Serum C1q- binding adiponectin in maintenance hemodialysis patients

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Kishida, Ken ^a,b   Kishida, Naohiro ^b   Arima, Masaaki ^b   Nakatsuji, Hideaki ^a   Kobayashi, Hironori ^c   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kishida Clinic   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adiponectin; C1q; C1q binding adiponectin; Hemodialysis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOSPHATE BLOOD LEVEL; THORACIC AORTA ANEURYSM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; COMPLEMENT C1Q; CORONARY ARTERY DISEASE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84874651009     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-50     Document Type: Article

References (24)

1. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y, Biochem Biophys Res Commun 1996 257 79 83 (Pubitemid 29299050)
2. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y, Diabetes 2002 51 2734 2741 10.2337/diabetes.51.9.2734 12196466 (Pubitemid 34970926)
3. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Kishida K, Funahashi T, Shimomura I, Endocr Metab Immune Disord Drug Targets 2012 12 118 131 10.2174/187153012800493468 22236026
4. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, J Am Soc Nephrol 2002 13 134 141 11752030 (Pubitemid 34042020)
5. Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio. Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H, Akamatsu S, Funahashi T, Shimomura I, Metabolism 2013 62 109 120 10.1016/j.metabol.2012.06.006 22819529
6. Adiponectin as a biomarker of the metabolic syndrome. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T, Circ J 2004 68 975 981 10.1253/circj.68.975 15502375 (Pubitemid 39540124)
7. Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics. Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I, Metabolism 2013 62 376 385 10.1016/j.metabol.2012.08.009 23058931
8. High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I, Metabolism 2012 in press
9. The Senri Study II Group: Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio without changes in body mass index in people with type 2 diabetes. Nakatsuji H, Kishida K, Kobayashi H, Funahashi T, Shimomura I, Diabetes Res Clin Pract 2013 99 14 e17 10.1016/j.diabres.2012.10.003 23142017
10. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, Okada T, Nakagawa Y, Tamba S, Kuroda Y, Hayashi N, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Funahashi T, Matsuzawa Y, Osaka CAD Group, Circ J 2008 72 23 28 10.1253/circj.72.23 18159094 (Pubitemid 351413321)
11. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Am J Kidney Dis 1998 31 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176
12. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
13. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK, Hemodial Int 2007 11 340 348 10.1111/j.1542-4758.2007.00190.x 17576300 (Pubitemid 46958589)
14. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T, Ther Apher Dial 2008 12 42 48 10.1111/j.1744-9987.2007. 00539.x 18257811 (Pubitemid 351197451)
15. Relationships between plasma adiponectin and blood cells, hepatopancreatic enzymes in women. Matsubara M, Namioka K, Katayose S, Thromb Haemost 2004 91 360 366 14961165 (Pubitemid 38240183)
16. Adiponectin and smoking status: a systematic review. Kotani K, Hazama A, Hagimoto A, Saika K, Shigeta M, Katanoda K, Nakamura M, J Atheroscler Thromb 2012 19 787 794 10.5551/jat.11833 22653164
17. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS, HEMO Study Group, Nephrol Dial Transplant 2008 23 2619 2628 10.1093/ndt/gfn070 18334528
18. Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. Okano K, Ohba T, Matsugami K, Uchida K, Nitta K, Kabaya T, Intern Med 2008 47 1379 1386 10.2169/internalmedicine.47. 1145 18670142
19. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, Yamamoto T, Hishida A, Intern Med 2008 47 485 491 10.2169/internalmedicine.47. 0614 18344634 (Pubitemid 351663663)
20. Relationship of high-molecular-weight adiponectin levels to visceral fat accumulation in hemodialysis patients. Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K, Intern Med 2010 49 299 305 10.2169/internalmedicine.49.2905 20154435
21. Adiponectin and cardiovascular outcomes among hemodialysis patients. Abdallah E, Waked E, Nabil M, El-Bendary O, Kidney Blood Press Res 2012 35 247 253 10.1159/000334649 22286012
22. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Amira OC, Naicker S, Manga P, Sliwa K, Mia A, Raal F, Crowther NJ, Immelman RA, Olorunju S, Hemodial Int 2012 16 59 68 22099423
23. Complement activation and C1q binding activity in haemodialysis. Dodd NJ, Vergani D, Turney JH, Parsons V, Weston MJ, Proc Eur Dial Transplant Assoc 1981 18 300 304 6977138
24. Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis. Inoshita H, Ohsawa I, Kusaba G, Ishii M, Onda K, Horikoshi S, Ohi H, Tomino Y, BMC Nephrol 2010 11 34 10.1186/1471-2369-11-34 21134272